Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
9
×
life sciences
national blog main
sanofi
9
×
biotech
clinical trials
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
amgen
cancer
fda
ipo
boulder/denver blog main
boulder/denver top stories
cancer drugs
deals
detroit blog main
detroit top stories
glaxosmithkline
inclisiran
indiana blog main
indiana top stories
investing
national
new york
pcsk9
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
What
medicines
drug
cancer
cholesterol
ipo
new
bio
disease
known
lowering
medco
proteins
research
revolution
roundup
targets
therapeutics
wave
week
abbvie’s
aces
acquire
address
adds
ago
agreed
ahead
allosteric
announced
big
billion
biofourmis
black
brings
bucks
cancer’s
cash
celebrate
ceo
chance
Language
unset
9
×
Current search:
unset
×
" boston top stories "
×
sanofi
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)